Efficacy of Topical Bevacizumab for Inhibiting Growth of Impending Recurrent Pterygium

REFERENCES

• Cheng HC, Tseng SH, Kao PL, et al. Low-dose intraoperative mitomycin C as chemoadjuvant for pterygium surgery. Cornea 2001;20:24–29.
   PubMed Web of Science ®Google Scholar
• Rodriguez JA, Ferrari C, Hernández GA. Intraoperative application of topical mitomycin C 0.05% for pterygium surgery. Bol Assoc Med P R 2004;96:100–102.
   PubMedGoogle Scholar
• Rahman A, Yahya K, Ul Hasan KS. Recurrence rate of pterygium following surgical excision with intraoperative versus postoperative mitomycin-C. J Coll Physicians Surg Pak 2008;18:489–492.
   PubMed Web of Science ®Google Scholar
• Varssano D, Michaeli-Cohen A, Loewenstein A. Excision of pterygium and conjunctival autograft. Isr Med Assoc J 2002;4:1097–1100.
   PubMed Web of Science ®Google Scholar
• Bahar I, Kaiserman I, Weisbrod M, et al. Extensive versus limited pterygium excision with conjunctival autograft: Outcomes and recurrence rates. Curr Eye Res 2008;33:435–440.
   PubMed Web of Science ®Google Scholar
• Liu S, Peng H, Liu Y, et al. Amniotic membrane transplantation and limbal autograft transplantation for patients with recurrent pterygium. Yan Ke Xue Bao 2007;23:227–230.
   PubMedGoogle Scholar
• Jain AK, Bansal R, Sukhija J. Human amniotic membrane transplantation with fibrin glue in management of primary pterygia: A new tuck-in technique. Cornea 2008;27:94–99.
   PubMed Web of Science ®Google Scholar
• Vastine DW, Stewart WB, Schwab IR. Reconstruction of the periocular mucous membrane by autologous conjunctival transplantation. Ophthalmology 1982;89:1072–1081.
   PubMed Web of Science ®Google Scholar
• Isohashi F, Inoue T, Xing S, et al. Postoperative irradiation for pterygium: Retrospective analysis of 1253 patients from the Osaka University Hospital. Strahlenther Onkol 2006;182:437–442.
   PubMed Web of Science ®Google Scholar
• Prabhasawat P, Tesavibul N, Leelapatranura K, et al. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology 2006;113:1102–1109.
   PubMed Web of Science ®Google Scholar
• Pherwani A, Vakil V, Eatamadi H, et al. Postoperative subconjunctival 5-fluorouracil in the management of recurring pterygium. Br J Ophthalmol 2007;91:398–399.
   PubMed Web of Science ®Google Scholar
• Bekibele CO, Baiyeroju AM, Olusanya BA, et al. Pterygium treatment using 5-FU as adjuvant treatment compared to conjunctiva autograft. Eye 2008;22:31–34.
   PubMed Web of Science ®Google Scholar
• Ioachim-Velogianni E, Tsironi E, Agnantis N, et al. HLA-DR antigen expression in pterygium epithelial cells and lymphocyte subpopulations: An immunohistochemistry study. Ger J Ophthalmol 1995;4:123–129.
   PubMedGoogle Scholar
• Lee DH, Cho HJ, Kim JT, et al. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 2001; 20:738–742.
   PubMed Web of Science ®Google Scholar
• Marcovich AL, Morad Y, Sandbank J, et al. Angiogenesis in pterygium: Morphometric and immunohistochemical study. Curr Eye Res 2002;25:17–22.
   PubMed Web of Science ®Google Scholar
• Jin J, Guan M, Sima J, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 2003;22:473–477.
   PubMed Web of Science ®Google Scholar
• Gebhardt M, Mentlein R, Schaudig U, et al. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology 2005;112:1023–1030.
   PubMed Web of Science ®Google Scholar
• Yan M, Li Z, Liu G, et al. Blood vessel multiply and significance of expression of Cox-2, VEGF in pterygium. Yan Ke Xue Bao 2007;23:20–24.
   PubMedGoogle Scholar
• Aspiotis M, Tsanou E, Gorezis S, et al. Angiogenesis in pterygium: Study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye 2007;21:1095–1101.
   PubMed Web of Science ®Google Scholar
• Lee JK, Song YS, Ha HS, et al. Endothelial progenitor cells in pterygium pathogenesis. Eye 2007;21:1186–1193.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581–611.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328–335.
   PubMed Web of Science ®Google Scholar
• Lien S, Lowman HB. Therapeutic anti-VEGF antibodies. Handbook Exp Pharmacol 2008;181:131–150.
   PubMedGoogle Scholar
• Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson Syndrome. Cornea 2008;27:70–73.
   PubMed Web of Science ®Google Scholar
• Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115:e33–e38.
   PubMed Web of Science ®Google Scholar
• Yoeruek E, Ziemssen F, Henke-Fahle S, et al; Tübingen Bevacizumab Study Group. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eye drops in corneal neovascularization after chemical burn. Acta Ophthalmol 2008;86:322–328.
   PubMed Web of Science ®Google Scholar
• Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804–807.
   PubMed Web of Science ®Google Scholar
• Prabhasawat P, Barton K, Burkett G, et al. Comparison of conjunctival autografts, amniotic membrane grafts and primary closure for pterygium excision. Ophthalmology 1997;104:974–985.
   PubMed Web of Science ®Google Scholar
• Hosseini H, Nejabat M, Mehryar M, et al. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol 2007;35:745–748.
   PubMed Web of Science ®Google Scholar
• Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 2007;69:925–927.
   PubMed Web of Science ®Google Scholar
• Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 2008;33:23–28.
   PubMed Web of Science ®Google Scholar
• Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevacizumab on primary pterygium. Cornea 2009;28:468–470.
   PubMed Web of Science ®Google Scholar
• Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: Results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009;127:381–389.
   PubMedGoogle Scholar
• Nomoto H, Shiraga F, Kuno N, et al. pharmacokinetics of bevacizumab after topical, subconjunctival and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50(10):4807–4813.
   PubMed Web of Science ®Google Scholar
• Bock F, Onderka J, Rummelt C, et al. Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 2009;50:2095–2102.
   PubMed Web of Science ®Google Scholar
• Koenig Y, Bock F, Horn F, et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247(10):1375–1382.
   PubMed Web of Science ®Google Scholar
• Wu PC, Kuo HK, Tai MH, et al. Topical bevacizumab eye drops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 2009;28: 103–104.
   PubMed Web of Science ®Google Scholar